[Skip to Content]
[Skip to Content Landing]
Views 90
Citations 0
Comment & Response
June 2018

Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia—Reply

Author Affiliations
  • 1Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China
  • 2Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Duke Cancer Institute, Durham, North Carolina
JAMA Oncol. 2018;4(6):891. doi:10.1001/jamaoncol.2018.0367

In Reply We appreciate Dr Gale’s interest in our recent article in JAMA Oncology.1 He raised 2 important questions: (1) There were no controls. (2) There was concern about patient selection in the older subject cohorts. We agree.

In contrast to our initial report, in this article from the Microtransplantation Interest Group, the primary end point of the study was to evaluate complete remission rate and overall survival of HLA-mismatched microtransplantation in older patients with acute myeloid leukemia among the different age subgroups ranging from 60 to 85 years. The results showed that the overall complete remission rate was 74.6% and the 2-year overall survival was 50.2%, which was similar to our initial randomized clinical trial.2 Importantly, the complete remission rate was not significantly different among the 4 age groups although the overall survival was better in the younger patients.